ReviewAnnual review of physiology2021
Renal Denervation to Treat Heart Failure.
Review in Annual review of physiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- A meta-analysis and review on the effectiveness and safety of renal denervation in managing heart failure with reduced ejection fraction.Renal failure · 2024Pooled it
- Three-Year Durability of Radiofrequency Renal Denervation: SPYRAL HTN-ON MED.Journal of the American Heart Association · 2026Trial
- Effects of sympathomodulation on pulse wave properties in heart failure with preserved ejection fraction.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Left ventricular sphericity indexes by gated single photon emission computed tomography myocardial perfusion imaging: potential opportunities and challenges for cardiac remodeling and clinical prognosis-a narrative review.Quantitative imaging in medicine and surgery · 2025Review
- Cardiorenal Syndrome and Autonomic Overactivity.Biomedicines · 2025Review
- 3-TYP protects against heart failure with preserved ejection fraction by inhibiting Sirtuin 3.Journal of molecular histology · 2025Article
- Renal denervation improves cardiac function and exercise duration in a miniswine model of heart failure with preserved ejection fraction.European journal of heart failure · 2025Article
- Peripheral blood mesenchymal stem cell-derived exosomes improve renal sympathetic denervation efficacy through β-catenin-mediated cardiac reprogramming.Clinical and translational medicine · 2025Article
- Ultrasound Renal Denervation Attenuates Early Cardiac Remodeling After Acute Myocardial Infarction in a Swine Model of Hypertensions and Dyslipidemia: A Pilot Study.Clinical and translational science · 2025Article
- Renal denervation in the setting of heart failure.Heart failure reviews · 2025Review
- Non-alcoholic fatty liver disease enhances the beneficial effect of renal denervation on gut microbiota aberrations in rats with heart failure.BMC microbiology · 2025Article
- Heart rate variability in cardiovascular disease diagnosis, prognosis and management.Frontiers in cardiovascular medicine · 2025Review
- Cardiorenal Syndrome in Heart Failure with Preserved Ejection Fraction: Insights into Pathophysiology and Recent Advances.Cardiorenal medicine · 2025Review
- Effects of renal denervation on the course of cardiorenal syndrome: insight from studies with fawn-hooded hypertensive rats.Physiological research · 2024Article
- Renal denervation improves cardiac function independently of afterload and restores myocardial norepinephrine levels in a rodent heart failure model.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Biomarker for cardiorenal syndrome risk in patients with liver cirrhosis and type 2 diabetes in Saudi Arabia.Saudi medical journal · 2024Article
- Renal sympathetic denervation improves pressure-natriuresis relationship in cardiorenal syndrome: insight from studies with Ren-2 transgenic hypertensive rats with volume overload induced using aorto-caval fistula.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Advances in device-based treatment of heart failure with preserved ejection fraction: evidence from clinical trials.ESC heart failure · 2024Review
- Atherogenic index of plasma: a new indicator for assessing the short-term mortality of patients with acute decompensated heart failure.Frontiers in endocrinology · 2024Article
- Percutaneous Strategies in Structural Heart Diseases: Focus on Chronic Heart Failure.Arquivos brasileiros de cardiologia · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Heart failure (HF) is a global pandemic with a poor prognosis after hospitalization. Despite HF syndrome complexities, evidence of significant sympathetic overactivity in the manifestation and progression of HF is universally accepted. Confirmation of this dogma is observed in guideline-directed use of neurohormonal pharmacotherapies as a standard of care in HF. Despite reductions in morbidity and mortality, a growing patient population is resistant to these medications, while off-target side effects lead to dismal patient adherence to lifelong drug regimens. Novel therapeutic strategies, devoid of these limitations, are necessary to attenuate the progression of HF pathophysiology while continuing to reduce morbidity and mortality. Renal denervation is an endovascular procedure, whereby the ablation of renal nerves results in reduced renal afferent and efferent sympathetic nerve activity in the kidney and globally. In this review, we discuss the current state of preclinical and clinical research related to renal sympathetic denervation to treat HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.